Recognizing the Early Signs of Tysabri-Associated PML

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Communication

If you or a loved one is taking Tysabri, understanding the earliest symptoms of progressive multifocal leukoencephalopathy (PML) can be critical. Decades of pharmacovigilance have established a clear pattern of clinical red flags that signal the onset of this rare but serious brain infection. This page outlines the typical timeline of PML development and the key symptoms that require immediate medical attention.

Find Out If You Qualify for Compensation →

Medical Evidence Linking Tysabri to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease in adults. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Illinois who have developed PML after Tysabri exposure, understanding the medical evidence and legal considerations—including the statute of limitations for filing a claim—is essential. The U.S. Food and Drug Administration (FDA) has assigned a boxed warning to Tysabri, stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is based on clinical evidence that PML occurs in patients receiving Tysabri, particularly those with specific risk factors. The FDA-identified risk factors include "the presence of anti-JCV antibodies, duration of therapy, and prior use of immunosuppressants" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who are anti-JCV antibody positive have a higher risk, and longer treatment duration—especially beyond two years—further elevates that risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, prior use of immunosuppressants compounds the risk, as these agents can further compromise immune function.

Mechanism and Clinical Presentation of PML

The mechanistic pathway linking Tysabri to PML involves the drug's mode of action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier. This reduces inflammation in the central nervous system but also impairs immune surveillance against the JC virus. Under normal conditions, the JC virus remains latent in the kidneys and lymphoid tissue. However, when immune trafficking to the brain is suppressed, the virus can reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the characteristic lesions of PML. Clinical presentation of PML typically includes progressive neurological deficits such as hemiparesis, visual disturbances, cognitive decline, and ataxia. Diagnosis is confirmed by MRI findings of multifocal white matter lesions and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction. The adequacy of warnings regarding Tysabri and PML has been a central issue in litigation. The FDA requires that Tysabri be prescribed only through the TOUCH Prescribing Program, a restricted distribution system designed to ensure that patients are informed of the risks and monitored for symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients must read the Medication Guide, understand the risks, and sign a Patient Enrollment Form. Healthcare professionals are instructed to "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and to "withhold TYSABRI immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, questions have arisen about whether prescribers and manufacturers adequately communicated the magnitude of risk, particularly for patients with multiple risk factors.

Statute of Limitations for Tysabri Claims in Illinois

For affected patients in Illinois, settlement-related considerations depend on the timeline between exposure and documented harm. PML can develop months to years after initiating Tysabri, and the latency period complicates the determination of when a claim accrues. In Illinois, the statute of limitations for personal injury claims generally is two years from the date the injury was discovered or reasonably should have been discovered. For PML, this discovery date may be when a patient receives a definitive diagnosis via MRI and CSF analysis, or when symptoms become severe enough to prompt medical investigation. Given that PML often leads to severe disability or death, the window for filing a claim is critical. Patients or their families should consult with legal counsel promptly to assess whether the statute of limitations has been met. Settlements in Tysabri-related PML cases have historically considered factors such as the severity of neurological impairment, the duration of Tysabri use, the presence of anti-JCV antibodies, and whether the patient had prior immunosuppressant exposure. The FDA's boxed warning explicitly states that these factors "should be considered in the context of expected benefit when initiating and continuing treatment with TYSABRI" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). In litigation, plaintiffs may argue that the warnings were insufficient to allow patients and physicians to make fully informed decisions, particularly for those who developed PML despite having no identifiable risk factors.

Conclusion and Next Steps

In summary, the medical evidence clearly establishes that Tysabri increases the risk of PML, with identifiable risk factors including anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use. The clinical presentation and diagnosis of PML are well-defined, and the mechanistic link through impaired immune surveillance is understood. For Illinois patients, the statute of limitations for filing a claim is a critical factor that depends on the date of diagnosis or discovery of harm. Given the severe outcomes associated with PML, timely legal consultation is recommended to preserve the right to seek compensation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in Illinois?

In Illinois, the statute of limitations for personal injury claims generally is two years from the date the injury was discovered or reasonably should have been discovered. For PML, this discovery date may be when a patient receives a definitive diagnosis via MRI and CSF analysis, or when symptoms become severe enough to prompt medical investigation.

What are the risk factors for developing PML while on Tysabri?

The FDA-identified risk factors include the presence of anti-JCV antibodies, duration of therapy (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA Boxed Warning for Tysabri

Find Out If You Qualify for Compensation

Statutes of limitations can limit the time you have to file a claim. A records screening is free and confidential.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.